In the current retrospective real-world study, we compared the efficacy, safety, patients compliance, and cost of RIT + 1 dose of pretreatment anti-IgE with conventional AIT in pediatric patients with mites-induced allergies treated at our center during recent years. The gene discussed is IGHE; the disease is Allergy.